Skip To Main Content
Sriram Krishnan on Muck Rack

Sriram Krishnan

As seen in: Holistic Women's Health, Medium, The New York Times, Forbes, HuffPost, Blackberry Blog, Substack, Mint, Observer, The Daily Dot and
ex-white house, a16z. sriramk.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sriram

Contact Sriram, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Why 2026 Is The Year AI Becomes A Partner, Not Just A Processor, In Drug Development

|
By Sriram Krishnan
| Forbes Verified
Sriram Krishnan, Ph.D., Chief Product Officer at Target RWE; 20+ years building health tech, inventor on 28 patents, author of 30+ papers. ​As the chief product officer at Target RWE, a health technology company, and having over 20 years of experience in digital health and artificial intelligence (AI), I've closely watched AI spend the last few years proving what it can do in drug development.
Open in Who Shared Issue with article?

Secufusion Introduces Unified AI Detection & Response (AIDR) to Secure AI Copilots, Agents, and Browser Workflows

|
By Sriram Krishnan
| EIN Presswire
A new security layer built for the AI‑powered workspace—protecting copilots, agents, and browser‑based work in real time Enterprises and MSSPs need a unified way to secure AI interactions without adding complexity,” “Secufusion delivers exactly that—neutrality, simplicity, and scalability.” — Miles Dunbar, COO at Cyberforce Security.
Open in Who Shared View Duplicates (68) Issue with article?

Anti signals

|
By Sriram Krishnan
| Substack
There is not much material on what anti-signals early-stage startup investors look for in teams and companies to pass, so I pinged some early-stage investor friends about what theirs are and shared their answers, anonymized, below.
Open in Who Shared Issue with article?
See all 59 licensed articles (75 Total)